Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published ...

A new phase 3 trial shows that DPP-1 inhibition with brensocatib reduces exacerbations and slows lung function decline in ...

NEJM Publishes New Global Clinical Trial Findings Showing Potential Power of Investigational Medication to Improve ...

Brensocatib significantly reduced the rate of pulmonary exacerbations and slowed lung function decline in patients with ...

For further information, please contact Professor Dr Felix Ringshausen, [email protected], telephone (0511) 532-3595. The original paper ‘Phase 3 Trial of the DPP1 Inhibitor Brensocatib ...

The dipeptidyl peptidase 1 (DPP-1) inhibitor cut the annualized rate of pulmonary exacerbations by around 20% compared with ...

19 In the phase 2 WILLOW trial involving adults with bronchiectasis, treatment with a 10-mg or 25-mg dose of brensocatib, administered once daily for 24 weeks, prolonged the time to the first ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 ...

Drug developer Insmed has filed a new drug application with the FDA based on the data with hopes that brensocatib could become the first approved treatment for patients with bronchiectasis as well ...

Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis, chronic rhinosinusitis ...

About Brensocatib Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis ...